视网膜疾病的患病率与医疗保健差异:一项荟萃分析
该研究采用贝叶斯荟萃回归分析NHANES、Medicare和MarketScan商业保险索赔及人群研究数据,更新2022年美国AMD、DR、DME和RVO的年龄标化患病率。结果显示各病患病率存在性别、种族和地区差异,提示显著的医疗负担与资源分配不均。
要点
- 2022年美国年龄标化患病率:AMD为5677/10万,DR为2710/10万,DME为317/10万,RVO为214/10万。
- 白种人AMD患病率比黑种人高1.7倍,RVO患病率比西班牙裔高2倍。
- 黑种人DR患病率比白种人高2倍以上,DME高4.6倍;西班牙裔DR高1.8倍,DME高3.7倍。
核心结论
- 2022年美国视网膜疾病患病率显著,构成相当大的医疗负担。
- 研究识别的性别、种族和地区差异可指导资源分配并改善服务水平不足社区的治疗可及性。
研究设计与样本
- 贝叶斯荟萃回归分析,数据来源于NHANES(2005-2008和2017-2020年3月)、Medicare按服务收费索赔(2017-2019)、IBM MarketScan商业保险索赔(2016)及符合条件的人群研究。
- AMD估计年龄≥40岁,DR和DME按糖尿病患者比例估计(所有年龄),RVO估计年龄≥18岁。
- 年龄标化使用2010年美国人口普查年龄金字塔。
主要发现
- 2022年每10万人年龄标化患病率:AMD为5677(95%不确定性区间[UI],4513-7374),DR为2710(95% UI,2112-3647),DME为317(95% UI,243-505),RVO为214(95% UI,168-409)。
- 所有疾病的患病率男性均高于女性。
- 白种人AMD患病率是黑种人的1.7倍,RVO患病率是西班牙裔的2倍。
- 黑种人DR患病率是白种人的2倍以上,DME患病率是白种人的4.6倍;西班牙裔DR患病率是白种人的1.8倍,DME是白种人的3.7倍。
- 州级患病率(每10万人):AMD为3497至7214,DR为1654至3607,DME为126至504,RVO为157至273。
临床怎么用
- 更新的患病率估计和识别的差异可用于指导美国医疗资源分配。
- 有助于制定改善服务水平不足社区治疗可及性和患者结局的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), and retinal vein occlusion (RVO) are leading causes of vision impairment and can lead to permanent, irreversible blindness. OBJECTIVE: To update age-standardized prevalence estimates for AMD, DR, DME, and RVO by gender, race and ethnicity, and US state or county for 2022. DATA SOURCES: The National Health and Nutrition Examination Survey (NHANES; 2005-2008 and 2017-March 2020), Medicare fee-for-service claims (2017-2019), IBM MarketScan commercial insurance claims (2016), and eligible population-based studies. DATA EXTRACTION AND SYNTHESIS: Bayesian meta-regression analysis of data sources containing prevalence information for AMD, DR, DME, and RVO in the US. Data were analyzed from March to September 2024. MAIN OUTCOMES AND MEASURES: AMD prevalence was estimated for ages 40 years and older and reported as total AMD (inclusive of early and late stage). DR (stratified by vision threatening and non-vision threatening) and DME prevalence were estimated across all ages as a proportion of people with diabetes (as defined in NHANES). RVO, defined by the presence of either retinal branch or central vein occlusion, was estimated for ages 18 years and older. Age-standardized estimates were calculated using the 2010 US Census age pyramid. RESULTS: For 2022, age-standardized prevalence estimates per 100 000 people were 5677 (95% uncertainty interval [UI], 4513-7374) for AMD, 2710 (95% UI, 2112-3647) for DR, 317 (95% UI, 243-505) for DME, and 214 (95% UI, 168-409) for RVO. For all conditions, prevalence was higher in males than females. White individuals had 1.7-fold higher AMD prevalence than Black individuals and 2-fold higher RVO prevalence than Hispanic individuals; Black individuals had more than 2-fold higher DR prevalence and 4.6-fold higher DME prevalence than White individuals, and Hispanic individuals had 1.8-fold higher DR prevalence and 3.7-fold higher DME prevalence than White individuals. State-level prevalence (per 100 000 people) ranged from 3497 to 7214 for AMD, 1654 to 3607 for DR, 126 to 504 for DME, and 157 to 273 for RVO. CONCLUSIONS AND RELEVANCE: In this meta-analysis, the US prevalence of retinal conditions was substantial, highlighting a considerable health care burden. The updated estimates and sex, race and ethnicity, and regional disparities identified in this study could inform resource allocation across the US and aid in the development of approaches to improve treatment accessibility and patient outcomes for underserved communities.
引用
- Liu TYA, Ko S, Rosettie KL, et al. Prevalence and Health Care Disparities of Retinal Conditions: A Meta-Analysis. JAMA Ophthalmol. 2026. PMID: 41854587. doi:10.1001/jamaophthalmol.2026.0319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。